Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information

Objective To construct a nomogram prediction model for the treatment effect of anlotinib with the participation of traditional Chinese medicine syndrome elements on the patients with extensive-stage small cell lung cancer (ES-SCLC) who previously received multiple lines of chemotherapy. Methods The...

Full description

Bibliographic Details
Main Authors: WU Qiong, MA Junyan, DONG Liang, LI Chunyang, WANG Zhiwu
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2023-05-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
Online Access:http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1373
_version_ 1797808911546318848
author WU Qiong
MA Junyan
DONG Liang
LI Chunyang
WANG Zhiwu
author_facet WU Qiong
MA Junyan
DONG Liang
LI Chunyang
WANG Zhiwu
author_sort WU Qiong
collection DOAJ
description Objective To construct a nomogram prediction model for the treatment effect of anlotinib with the participation of traditional Chinese medicine syndrome elements on the patients with extensive-stage small cell lung cancer (ES-SCLC) who previously received multiple lines of chemotherapy. Methods The clinical data of 127 patients with ES-SCLC who received at least two cycles of anlotinib treatment were retrospectively studied. Kaplan-Meier method was used to analyze the relationship between each factor and the overall survival time. Cox regression analysis was applied to screen the independent influencing factors of the prognosis of patients with ES-SCLC. R language was employed to build a nomogram prediction model, C-index was used to evaluate the model, and calibration curve was adopted to verify the accuracy of the model. Results Age, PS score, brain metastases, qi deficiency syndrome, yin deficiency syndrome, and blood stasis syndrome were related risk factors for ES-SCLC treated with anlotinib. PS score, brain metastasis, and blood stasis syndrome were independent prognostic factors. On the basis of these three independent influencing factors, a nomogram model was established to predict the prognosis of patients with ES-SCLC treated with anlotinib. The predicted risk was close to the actual risk, showing a high degree of coincidence. Conclusion The nomogram model established with PS score, blood stasis syndrome elements, and brain metastasis as independent factors can predict the prognosis of patients with ES-SCLC receiving second- and third-line treatment of anlotinib.
first_indexed 2024-03-13T06:44:43Z
format Article
id doaj.art-db10685bbea34554a1be90e15529ec61
institution Directory Open Access Journal
issn 1000-8578
language zho
last_indexed 2024-03-13T06:44:43Z
publishDate 2023-05-01
publisher Magazine House of Cancer Research on Prevention and Treatment
record_format Article
series Zhongliu Fangzhi Yanjiu
spelling doaj.art-db10685bbea34554a1be90e15529ec612023-06-08T10:42:08ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782023-05-0150548348910.3971/j.issn.1000-8578.2023.22.13738578.2023.22.1373Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome InformationWU Qiong0MA Junyan1DONG Liang2LI Chunyang3WANG Zhiwu4The Second Department of Radiochemistry, Tangshan People's Hospital, Tangshan 063000, ChinaThe Second Department of Radiochemistry, Tangshan People's Hospital, Tangshan 063000, ChinaThe Second Department of Radiochemistry, Tangshan People's Hospital, Tangshan 063000, ChinaThe Second Department of Radiochemistry, Tangshan People's Hospital, Tangshan 063000, ChinaThe Second Department of Radiochemistry, Tangshan People's Hospital, Tangshan 063000, ChinaObjective To construct a nomogram prediction model for the treatment effect of anlotinib with the participation of traditional Chinese medicine syndrome elements on the patients with extensive-stage small cell lung cancer (ES-SCLC) who previously received multiple lines of chemotherapy. Methods The clinical data of 127 patients with ES-SCLC who received at least two cycles of anlotinib treatment were retrospectively studied. Kaplan-Meier method was used to analyze the relationship between each factor and the overall survival time. Cox regression analysis was applied to screen the independent influencing factors of the prognosis of patients with ES-SCLC. R language was employed to build a nomogram prediction model, C-index was used to evaluate the model, and calibration curve was adopted to verify the accuracy of the model. Results Age, PS score, brain metastases, qi deficiency syndrome, yin deficiency syndrome, and blood stasis syndrome were related risk factors for ES-SCLC treated with anlotinib. PS score, brain metastasis, and blood stasis syndrome were independent prognostic factors. On the basis of these three independent influencing factors, a nomogram model was established to predict the prognosis of patients with ES-SCLC treated with anlotinib. The predicted risk was close to the actual risk, showing a high degree of coincidence. Conclusion The nomogram model established with PS score, blood stasis syndrome elements, and brain metastasis as independent factors can predict the prognosis of patients with ES-SCLC receiving second- and third-line treatment of anlotinib.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1373anlotinibsmall cell lung cancertraditional chinese medicine syndrome elementspredictive model
spellingShingle WU Qiong
MA Junyan
DONG Liang
LI Chunyang
WANG Zhiwu
Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information
Zhongliu Fangzhi Yanjiu
anlotinib
small cell lung cancer
traditional chinese medicine syndrome elements
predictive model
title Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information
title_full Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information
title_fullStr Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information
title_full_unstemmed Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information
title_short Prediction Model of Treatment Effect of Anlotinib on Extensive-stage Small Cell Lung Cancer Based on Combination of Disease and Syndrome Information
title_sort prediction model of treatment effect of anlotinib on extensive stage small cell lung cancer based on combination of disease and syndrome information
topic anlotinib
small cell lung cancer
traditional chinese medicine syndrome elements
predictive model
url http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1373
work_keys_str_mv AT wuqiong predictionmodeloftreatmenteffectofanlotinibonextensivestagesmallcelllungcancerbasedoncombinationofdiseaseandsyndromeinformation
AT majunyan predictionmodeloftreatmenteffectofanlotinibonextensivestagesmallcelllungcancerbasedoncombinationofdiseaseandsyndromeinformation
AT dongliang predictionmodeloftreatmenteffectofanlotinibonextensivestagesmallcelllungcancerbasedoncombinationofdiseaseandsyndromeinformation
AT lichunyang predictionmodeloftreatmenteffectofanlotinibonextensivestagesmallcelllungcancerbasedoncombinationofdiseaseandsyndromeinformation
AT wangzhiwu predictionmodeloftreatmenteffectofanlotinibonextensivestagesmallcelllungcancerbasedoncombinationofdiseaseandsyndromeinformation